The Recall Desk
HighFDA (Devices)·Z-1231-2020·Announced 2020-02-26

Siemens Atellica CH Enzymatic Creatinine Reagent Recalled for Interference

Siemens Healthcare Diagnostics is recalling Atellica CH Enzymatic Creatinine reagent due to potential falsely depressed results for patients on phenindione therapy.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: The recall involves a risk-of-harm product (medical device reagent) where injury has not yet been reported, fitting the High severity criteria.

Plain-English summary

Siemens Healthcare Diagnostics, Inc. is recalling 824 units of Atellica CH Enzymatic Creatinine (ECRE_2) reagent, SMN 11097533. The recall covers all lots and was distributed nationwide in the United States.

The recall was initiated because there is a potential for falsely depressed creatinine results when using the enzymatic methodology for patients on phenindione therapy. The source text notes that this interference has not been observed with the creatinine Jaffe methodology.

Healthcare facilities and laboratories should stop using the affected reagent and contact Siemens Healthcare Diagnostics for further instructions or replacement.

The recalled product

Product
Atellica CH Enzymatic Creatinine (ECRE_2) reagent, SMN 11097533
Affected units
824

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • UDI Number: 00630414595795 Lots: All lots

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 4 recalled by Siemens Healthcare Diagnostics, Inc. under a single FDA (Devices) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 4 products in this recall →

Same manufacturer · Siemens Healthcare Diagnostics, Inc.

See all →